Programme

Cytokinetics logo

The 31st International Symposium on ALS/MND will be held virtually on 9-11 December 2020.

See below for the programme of platform presentations – including cutting-edge research talks with live Q&As and discussions from our invited plenary speakers, award presentations, and live poster sessions. Abstracts for each plenary presentation will be available on the website soon.

You can print the programme by clicking on the button at the bottom of this page. Please note that the programme is subject to change.

The Sponsor/Exhibitor Hall, Meeting hub (to network with fellow delegates), and the ePoster Hall (to preview posters before the live poster sessions) will be available throughout the virtual event.

DAY 1 (Wednesday 9 December)

SESSION 1: OPENING SESSION
GMTESTJST PRESENTATIONSPEAKER
1300 - 1305 0800 - 08052200 - 2205Welcome to the 31st International Symposium on ALS/MND
1305 - 1355

0805 - 08552205 - 2255#C1The Stephen Hawking Memorial Lecture:
Introduction
Targeting neuroinflammation across neurodegenerative diseases

L Hawking (UK)
R Tanzi (USA)
1355 - 14050855 - 09052255 - 2305International Alliance of ALS/MND Associations
Forbes Norris and Humanitarian Awards
1405 - 14200905 - 09202305 - 2320IPG Award and winner’s research presentation
SESSION 2: PROTEIN DYSREGULATION AND PROTEOTOXICITY
GMTESTJST PRESENTATIONSPEAKER
1430 - 1450 0930 - 09502330 - 2350#C2Prions, prionoids and neurodegenerationA Aguzzi (Switzerland)
1450 - 1510

0950 - 10102350 - 0010#C3Protein dysregulation in ALSD Bosco (USA)
1510 - 15301010 - 10300010 - 0030#C4Protein quality control of biomolecular condensates:
Implications for ALS and frontotemporal degeneration
S Carra (Italy)
1530 - 15401030 - 10400030 - 0040Discussion/Questions
SESSION 3: CLINICAL TRIALS
GMTESTJST PRESENTATIONSPEAKER
1550 - 1610 1050 - 11100050 - 0110#C5The REFALS phase 3 study of levosimendan in patients with ALSM Cudkowicz (USA)
1610 - 1630

1110 - 11300110 - 0130#C6NurOwn ALS Phase 3 clinical trial updateR Kern (Israel)
M Cudkowicz (USA)
1630 - 16501130 - 11500130 - 0150#C7Functional and long-term survival benefit of AMX0035 in ALS:
Results of the CENTAUR and Open Label Extension trials
S Paganoni (USA)
1650 - 17001150 - 12000150 - 0200Discussion/Questions

LIVE POSTER SESSION A

GMT: 1710 - 1750   |   EST: 1210 - 1250   |   JST: 0210 - 0250


 

DAY 2 (Thursday 10 December)

SESSION 4: FROM RESEARCH TO CARE
GMTESTJST PRESENTATIONSPEAKER
1300 - 13050800 - 08052200 - 2205Welcome
1305 - 1325 0805 - 08252205 - 2225#C8The power of ALS patient registries in the age of personalized medicineO Hardiman (Ireland)
1325 - 1345

0825 - 08452225 - 2245#C9Improving patient-reported outcome measures in ALS/MNDC Young (UK)
M Cudkowicz (USA)
1345 - 14050845 - 09052245 - 2305#C10Assessment of ALS disease progression from accelerometer and
voice recordings using machine learning with application
to the evaluation of real-world drug efficacy
S Perrin (USA)
1405 - 14150905 - 09152305 - 2315Discussion/Questions
SESSION 5: ALS/MND PATHOGENESIS
GMTESTJST PRESENTATIONSPEAKER
1430 - 1450 0930 - 09502330 - 2350#C11Spatiotemporal dynamics of molecular pathology in ALSH Phatnani (Ireland)
1450 - 15100950 - 10102350 - 0010#C12DNA methylation studies in ALS and age accelerationE Rogaeva (Canada)
1510 - 15301010 - 10300010 - 0030#C13Defective RNA metabolism in ALS: TDP-43 loss of function and
stress granule dynamics
C Vande Velde (Canada)
1530 - 15401030 - 10400030 - 0040Discussion/Questions
SESSION 6: THERAPEUTIC STRATEGIES
GMTESTJST PRESENTATIONSPEAKER
1550 - 16101050 - 11100050 - 0110#C14ASOs for neuromuscular diseases: Yesterday, today and tomorrowA Chio (Italy)
1610 - 16301110 - 11300110 - 0130#C15Modulating disease-modifying genes in ALSA Gitler (USA)
1630 - 16501130 - 11500130 - 0150#C16MR-guided focused ultrasound: A new frontier in the delivery
of biotherapeutics for ALS
L Zinman (Canada)
A Abrahao (Canada)
1650 - 17001150 - 12000150 - 0200Discussion/Questions

LIVE POSTER SESSION B

GMT: 1710 - 1750   |   EST: 1210 - 1250   |   JST: 0210 - 0250


 

DAY 3 (Friday 6 December)


LIVE POSTER SESSION C

GMT: 1205 - 1250   |   EST: 0705 - 0750   |   JST: 2105 - 2150


 

SESSION 7: PERSPECTIVES – LESSONS FROM COVID-19
GMTESTJST PRESENTATIONSPEAKER
1300 - 13050800 - 08052200 - 2205Welcome
1305 - 13350805 - 08352205 - 2235#C17Implications for clinical trials and drug developmentA Genge (Canada)
Impact on palliative care for ALS/MNDR Burman (UK)
Impact on basic and translational scienceC Bendotti (Italy)
Impact on living with ALS/MNDB Virgo (UK)
1335 - 14050835 - 09052230 - 2300Discussion/Questions
SESSION 8: COGNITIVE CHANGE
GMTESTJST PRESENTATIONSPEAKER
1420 - 14400910 - 09302310 - 2330#C18Are we there yet? Measuring nonmotor progression in ALSM Strong (Canada)
1440 - 15000930 - 09502330 - 2350#C19Selective vulnerability in frontotemporal dementia and ALSW Seeley (USA)
1500 - 15200950 - 10102350 - 0010#C20The role of the cerebellum in cognition: Implications for ALSJ Schmahmann (USA)
1520 - 15301010 - 10200010 - 0020Discussion/Questions
SESSION 9: CLOSING SESSION
GMTESTJST PRESENTATIONSPEAKER
1550 - 16001050 - 11000050 - 0100Invitation to Basel 2021
1600 - 16151100 - 11150100 - 0115Healey Center Award
1615 - 16401115 - 11400115 - 0140#C21Open drug discovery: From genes to affordable medicinesA Edwards (Canada)
1640 - 16501140 - 11500140 - 0150#C22ALS Diagnostic Criteria - The Gold StandardM Kiernan (Australia)
1650 - 17001150 - 12000150 - 0200Final thoughts

Symposium Programme Committee

Kevin Talbot (Chair of Programme Committee), Professor of Motor Neuron Biology, University of Oxford
Ammar Al-Chalabi (Incoming Chair of Programme Committee), Professor of Neurology and Complex Disease Genetics), King's College London
Nick Cole, Head of Research, Motor Neurone Disease Association
Brian Dickie, Director of Research Development, Motor Neurone Disease Association
Heather Durham, Professor, Montreal Neurological Institute, McGill University
Angela Genge, Director of the Clinical Research Unit, Montreal Neurological Institute, McGill University
Nick Goldup, Director of Care, Motor Neurone Disease Association
Sanjay Kalra, Professor of Neurology,  Neuroscience and Mental Health Institute, University of Alberta
Janice Robertson, Professor and Canada Research Chair in ALS, Tanz Centre for Research in Neurodegenerative Diseases
David Taylor, Vice President, Research, ALS Canada